focus -WSS

focus

author：knowledge 2025-10-01 20:16:35 - browse：353

Under a microscope, human prostate cancer cells, colorized in blue, appear in an air bubble — coverage from STAT — Under a microscope, human prostate cancer cells, colorized in blue, appear in an air bubble. Adobe

An early-stage clinical trial of a radiopharmaceutical drug developed by Johnson & Johnson showed some signs of efficacy in prostate cancer patients, newly released data show, but four participants in the trial died.

The drug, JNJ-6420, is designed to treat metastatic castration-resistant prostate cancer by delivering radioactive isotopes directly to cancer cells. Interest in such radiopharmaceuticals has skyrocketed following the approval of Pluvicto, which also treats prostate cancer.

In the Phase 1 data reported ahead of the American Society of Clinical Oncology meeting next week, 18% of participants on a mid-level dose of Johnson & Johnson’s treatment had a complete or partial response. For comparison, approximately 29.8% of the subjects in a Phase 3 trial of Pluvicto responded to the treatment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Advances in CAR

hotspot

WSS

Why Charlie Gard's case is so disturbing to Americans

'Make People Better': The CRISPR babies story you probably don't know

Crinetics acromegaly drug succeeds in late

Senate panel eyes new effort on drug shortages

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

The (many) problems with a new study criticizing cancer screening

hotspot

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

Medicare details structure of new drug price negotiation program

How to fix cancer clinical trials' diversity problem

Drug repurposing or repositioning? The language matters

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

Virginia high school admissions case could be legal follow

NIH nominee Bertagnolli will get October confirmation hearing

Anesthesiologist group: stop taking Ozempic before surgery

Stem cell treatment guidelines are released by FDA

Medical records are filled with copy

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

knowledge

How to fix cancer clinical trials' diversity problem

Colorectal cancer study finds potential in overlooked immune cell

What American doctors can learn from their Israeli counterparts

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

Was Amgen transparent enough on FDA's concern on cancer drug?

Medicaid rebukes states for mistakenly disenrolling children

knowledge

hotspot

Wikipedia

knowledge